Search
NRX Pharmaceuticals Inc
NRXPAdd to Watchlist
3.870USD
+0.010+0.26%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
140.21MMarket Cap
LossP/E TTM
More Details of NRX Pharmaceuticals Inc Company
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
NRX Pharmaceuticals Inc Info
Ticker SymbolNRXP
Company nameNRX Pharmaceuticals Inc
IPO dateNov 20, 2017
CEOJavitt (Jonathan C)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 20
Address1201 Orange Street
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19801
Phone14842546134
Websitehttps://www.nrxpharma.com/
Ticker SymbolNRXP
IPO dateNov 20, 2017
CEOJavitt (Jonathan C)
Company Executives of NRX Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Matthew P. Duffy
Mr. Matthew P. Duffy
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
FAQs
Who are the top five shareholders of NRX Pharmaceuticals Inc?
The top five shareholders of NRX Pharmaceuticals Inc are: Dr. Jonathan C. Javitt, M.D.
How many institutions hold shares of NRX Pharmaceuticals Inc (NRXP)?
As of 2026Q1, 74 institutions hold shares of NRX Pharmaceuticals Inc, with a combined market value of approximately 9.80M, accounting for 29.64% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5090061.00.